Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"LadRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LadRx Highlights Patent Issued for Its LADR Technology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"LadRx","sponsor":"XOMA","pharmaFlowCategory":"D","amount":"$11.0 million","upfrontCash":"Undisclosed","newsHeadline":"LadRx Completes Non-Dilutive Financing Transaction for up to $11 Million with XOMA Corporation","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"LadRx","sponsor":"XOMA","pharmaFlowCategory":"D","amount":"$58.6 million","upfrontCash":"$5.0 million","newsHeadline":"FDA Acceptance of Zevra's Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals by LadRx

    Menu

    LadRx

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              LadRx

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              FDA Acceptance of Zevra's Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx

              Details:

              Under the agreement, XOMA has acquired the royalty and milestone rights associated with two assets from LadRx Corporation, BRX-345 (arimoclomol), an oral therapeutic for Niemann-Pick disease type C, and aldoxorubicin, an albumin-linked formulation of doxorubicin.

              Lead Product(s): Arimoclomol

              Therapeutic Area: Rare Diseases and Disorders Product Name: BRX-345

              Highest Development Status: Phase II/ Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: XOMA

              Deal Size: $58.6 million Upfront Cash: $5.0 million

              Deal Type: Agreement January 11, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              LadRx

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              LadRx Completes Non-Dilutive Financing Transaction for up to $11 Million with XOMA Corporation

              Details:

              The Company expects to use the proceeds to advance its lead novel LADR-based anti-cancer drug, LADR-7 (AE-keto-sulf07) towards an IND filing with the FDA.

              Lead Product(s): AE-Keto-Sulf07

              Therapeutic Area: Oncology Product Name: LADR7

              Highest Development Status: IND Enabling Product Type: Large molecule

              Partner/Sponsor/Collaborator: XOMA

              Deal Size: $11.0 million Upfront Cash: Undisclosed

              Deal Type: Financing June 22, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              LadRx

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              LadRx Highlights Patent Issued for Its LADR Technology

              Details:

              INNO-206 (aldoxorubicin) is a prodrug of doxorubicin that binds endogenous albumin after administration. The bound doxorubicin is released in the acidic environment of the tumor cell through cleavage of an acid sensitive linker and expresses antitumor efficacy and toxicity.

              Lead Product(s): Aldoxorubicin

              Therapeutic Area: Oncology Product Name: INNO-206

              Highest Development Status: Phase II Product Type:

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 27, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY